芪参益气滴丸改善慢性心力衰竭患者心室重构和功能：一项汇总分析。
Qishenyiqi dripping pill improves ventricular remodeling and function in patients with chronic heart failure: A pooled analysis.
作者信息
Chang Mingzheng, Cheng Lei, Shen Yaqian, Zhang Ying, Zhang Zhongwen, Hao Panpan
机构信息
Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Department of Cardiology, Shandong University Qilu Hospital, School of Basic Medical Sciences of Shandong University.
Department of Endocrinology & Metabolism, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong, China.
出版信息
Medicine (Baltimore). 2019 Jan;98(2):e13906. doi: 10.1097/MD.0000000000013906.
BACKGROUND
Qishenyiqi dripping pill for chronic heart failure (CHF) remains controversial due to lack of high-quality trials. Therefore, we conduct this pooled-analysis to evaluate the efficacy and safety of Qishenyiqi in CHF patients.
METHODS
We searched for randomized clinical trials for Qishenyiqi dripping pill in treating CHF up to August 2018 through China National Knowledge Infrastructure (CNKI), the PubMed Database, the Wanfang Database, the China Scientific Journal Database (VIP), and the Chinese Biomedicine Literature Service System. RevMan 5.3 was used for pooled analyses. Based on the New York Heart Association (NYHA) classification, the clinical therapeutic effect was collected as the primary endpoint.
RESULTS
The efficacy and safety of Qishenyiqi combined with routine treatment significantly increased NYHA functional classification, left ventricular ejection fraction, cardiac index, and 6-minute walking test and decreased brain natriuretic peptide, left ventricular end-diastolic, and end-systolic dimensions with no obvious side effects in comparison with routine therapy alone.
CONCLUSIONS
Together these results provide important insights into Qishenyiqi is effective and safe in improving ventricular remodeling and function of CHF patients.
PROSPERO REGISTRATION NUMBER
PROSPERO106695.
背景
由于缺乏高质量试验，芪参益气滴丸治疗慢性心力衰竭（CHF）仍存在争议。因此，我们进行这项汇总分析以评估芪参益气对CHF患者的疗效和安全性。
方法
通过中国知网（CNKI）、PubMed数据库、万方数据库、维普中文科技期刊数据库（VIP）和中国生物医学文献服务系统，检索截至2018年8月芪参益气滴丸治疗CHF的随机临床试验。使用RevMan 5.3进行汇总分析。以纽约心脏协会（NYHA）分级为基础，收集临床治疗效果作为主要终点。
结果
与单纯常规治疗相比，芪参益气联合常规治疗的疗效和安全性显著提高了NYHA功能分级、左心室射血分数、心脏指数和6分钟步行试验结果，并降低了脑钠肽、左心室舒张末期和收缩末期内径，且无明显副作用。
结论
这些结果共同为芪参益气有效且安全地改善CHF患者的心室重构和功能提供了重要见解。
国际前瞻性系统评价注册编号
PROSPERO106695。
Zotero 插件